Cumberland posts Q3 net income of $77.8M on Apotex divestiture gain; plans ifetroban NDA in DMD

CUMBERLAND PHARMACEUTICALS INC

Net income of $77.8M in Q3 2026, driven by the gain on divestiture of commercial brands to Apotex Health, whose $100M strategic transaction closed July 1, 2026.
Cash and equivalents of $80.6M at September 30, 2026; total assets ~$114M, liabilities $42M and shareholders' equity $73M.
Will submit an NDA for ifetroban in DMD cardiomyopathy after a fall pre-NDA meeting; FDA granted a rolling review and conditionally accepted DYSCORBAN as the name.
Phase 2 FIGHT DMD showed a 5.4 percentage point LVEF improvement (p=0.002) in the high-dose group; safety database exceeds 1,400 subjects across ~30 studies.
Phase 2a ASSIST-SSc top-line: ifetroban generally well tolerated, no drug-related serious AEs over 12 months; Cumberland to submit the study report to FDA, SSc decision pending.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.